In addition, cetuximab is prone to drug resistance in the treatment of colon cancer, while its combination with ferroptosis inducer β-elemene can sensitize KRAS mutant colorectal cancer cells via inducing ferroptosis and inhibiting epithelial-mesenchymal transition (EMT) and is expected to provide a prospective treatment strategy for CRC patients with RAS mutant (Chen et al., 2020b). This evidence concerns the gene KRAS and colorectal carcinoma.